Neuraxis, Inc. (NRXS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Neuraxis, Inc. stock (NRXS) is currently trading at $7.05. Neuraxis, Inc. PS ratio (Price-to-Sales) is 24.32. Analyst consensus price target for NRXS is $11.00. WallStSmart rates NRXS as Sell.
- NRXS PE ratio analysis and historical PE chart
- NRXS PS ratio (Price-to-Sales) history and trend
- NRXS intrinsic value — DCF, Graham Number, EPV models
- NRXS stock price prediction 2025 2026 2027 2028 2029 2030
- NRXS fair value vs current price
- NRXS insider transactions and insider buying
- Is NRXS undervalued or overvalued?
- Neuraxis, Inc. financial analysis — revenue, earnings, cash flow
- NRXS Piotroski F-Score and Altman Z-Score
- NRXS analyst price target and Smart Rating
Neuraxis, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Neuraxis, Inc. (NRXS) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Neuraxis, Inc. (NRXS) Key Strengths (1)
Strong revenue growth at 21.70% annually
Supporting Valuation Data
Neuraxis, Inc. (NRXS) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 24.3x annual revenue
Very expensive at 35.6x book value
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Neuraxis, Inc. (NRXS) Detailed Analysis Report
Overall Assessment
This company scores 18/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 8.0/10) while 7 fall into concern territory (avg 1.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 21.70%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (24.32), Price/Book (35.59) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -3071.00%, Operating Margin at -258.80%, Profit Margin at -224.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -3071.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 21.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NRXS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NRXS's Price-to-Sales ratio of 24.32x trades 81% above its historical average of 13.45x (97th percentile), historically expensive. The current valuation is 0% below its historical high of 24.32x set in Mar 2026, and 211% above its historical low of 7.81x in Mar 2025. Over the past 12 months, the PS ratio has expanded from ~7.8x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Neuraxis, Inc. (NRXS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Neuraxis, Inc. is a strong growth company balancing expansion with improving profitability. Revenue reached 3M with 22% growth year-over-year. The company is currently unprofitable, posting a -224.2% profit margin.
Key Findings
Debt-to-equity ratio of 0.21 indicates a conservative balance sheet with 4M in cash.
The company is unprofitable with a -224.2% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Neuraxis, Inc. maintain 22%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.49, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Neuraxis, Inc..
Bottom Line
Neuraxis, Inc. offers an attractive blend of growth (22% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Neuraxis, Inc.(NRXS)
NYSE MKT
HEALTHCARE
BIOTECHNOLOGY
USA
NeurAxis, Inc. is a neuromodulation therapy device company in the United States. The company is headquartered in Versailles, Indiana.